PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07H 21/04, C07K 15/00, 15/28 C12N 1/00, 5/10, 9/12 C12N 15/00, C12Q 1/48, 1/68	A1	(11) International Publication Number: WO 93/01205 (43) International Publication Date: 21 January 1993 (21.01.93)

(21) International Application Number: PCT/US92/05565

(22) International Filing Date: 1 July 1992 (01.07.92)

(30) Priority data:
728,783 3 July 1991 (03.07.91) US

(71) Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventor: HOEKSTRA, Merl, F. ; 583 Rockport Court, Leucadia, CA 92024 (US).

(74) Agents: WETHERELL, John, R., Jr. et al.; Spensley Horn Jubas & Lubitz, 1880 Century Park East, Suite 500, Los Angeles, CA 90067 (US).

(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).

Published
With international search report.

(54) Title: TYROSINE KINASE

(57) Abstract

Tyrosine kinase mutant and wild-type genes useful in screening compositions which may affect DNA double-strand break repair activity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		
ES	Spain	MG	Madagascar		

TYROSINE KINASE

BACKGROUND OF THE INVENTION

1. Field of The Invention

This invention relates generally to the molecular cloning of genes which can be used in toxicity assays and, specifically, to the isolation of a mammalian DNA recombination and repair gene which can be used in an assay to screen various compositions which affect DNA repair.

2. Related Art

Chromosomes experience single-stranded or double-stranded breaks as a result of energy-rich radiation, chemical agents, as well as spontaneous breaks occurring during replication among others. Although genes present in the chromosomes undergo continuous damage, repair, exchange, transposition, and splicing, certain enzymes protect or restore the specific base sequences of the chromosome.

The repair of DNA damage is a complex process that involves the coordination of a large number of gene products. This complexity is in part dependent upon both the form of DNA damage and cell cycle progression. For example, in response to ultraviolet (UV) irradiation, cells can employ photoreactivation or excision repair functions to correct genetic lesions. The repair of strand breaks, such as those created by X-rays, can proceed through recombinational mechanisms. For many forms of DNA damage, the cell is induced to arrest in the G2 phase of the cell cycle. During this G2 arrest, lesions are repaired to ensure chromosomal integrity prior to mitotic segregation.

Since the transfer of genetic information from generation to generation is dependent on the integrity of DNA, it is important to identify those gene products which affect or regulate genetic recombination and repair. Through the use of organisms with specific genetic mutations, the normal functional gene can be obtained, molecularly cloned, and the gene products studied.

Phenotypic complementation, as a way of identifying homologous normal functional genes, is widely used. For example, the human homologue of the yeast cell cycle control gene, cdc 2, was cloned by expressing a human cDNA library in *Schizosaccharomyces pombe* and selecting those clones which could complement a mutation in the yeast cdc 2 gene (Lee, *et al.*, *Nature*, 327:31, 1987). A mammalian gene capable of reverting the heat shock sensitivity of the $RAS2^{val19}$ gene of yeast, has also been cloned by using complementation (Colicelli, *et al., Proc.Nat'l.Acad.Sci. USA*, 86:3599, 1989). A rat brain cDNA library was used to clone a mammalian cDNA that can complement the loss of growth control associated with the activated RAS2 gene in yeast. The gene, DPD (dunce-like phosphodiesterase), encodes a high-affinity CAMP phosphodiesterase.

In eukaryotes such as *Saccharomyces cerevisiae*, genetic studies have defined repair-deficient mutants which have allowed the identification of more than 30 radiation-sensitive (*RAD*) mutants (Haynes, *et al.*, in *Molecular Biology of the Yeast Saccharomyces*, pp. 371, 1981; J. Game *in Yeast Genetics: Fundamental and Applied Aspects*, pp. 109, 1983). These mutants can be grouped into three classes depending upon their sensitivities. These classes broadly define excision-repair, error-prone repair, and recombinational-repair functions. The molecular characterization of yeast *RAD* genes has increased the understanding of the enzymatic machinery involved in excision repair, as well as the arrest of cell division by DNA damage.

The understanding of RAD genes and their expression products has become increasingly important as research continues to develop more effective therapeutic compositions. Often these new compositions appear quite effective against a particular disease condition, such as certain tumors, but prove to be too toxic for *in vivo* therapy in an animal having the disease. Indeed, these compositions can actually increase the likelihood of mutagenesis.

Most agents that are mutagenic or carcinogenic are in themselves unreactive, but are broken down to reactive intermediates *in vivo*. It is these reactive intermediates which interact with DNA to produce a mutation. This event is thought to be the initial step in chemical carcinogenesis. Mutations in a large number of genes affect the cellular response to agents that damage DNA. In all likelihood, many of these mutated genes encode enzymes that participate in DNA repair systems. Consequently, when the repair system is compromised, the cells become extremely sensitive to toxic agents. Although the DNA may revert to normal when DNA repair mechanisms operate successfully, the failure of such mechanisms can result in a transformed tumor cell which continues to proliferate.

Although there are currently available tests to determine the toxicity or mutagenicity of chemical agents and compositions, there are limitations in both laboratory screening procedures and animal toxicity tests. These limitations include extrapolating laboratory data from animals to humans. There is often a large measure of uncertainty when attempting to correlate the results obtained in laboratory animals with effects in human subjects. In most cases, doses of the test drug have been used in the animal which are too high to be safely administered to humans. In addition, some types of toxicity can be detected if the drug is administered in a particular species, yet may be missed if the experiment is not done in the correct animal

species. Moreover, many currently available laboratory tests are incapable of detecting certain types of toxic manifestations which occur in man.

Drugs are also routinely tested for their mutagenic potential using microorganisms in the screening assay. The popular test developed by Ames and colleagues (Ames, *et al., Mutat. Res.*:31, 347, 1975) uses *Salmonella typhimurium* containing a mutant gene for histidine synthesis. This bacterial strain cannot grow in a histidine deficient medium unless a reverse mutation is induced by exposure to a particular agent. The Ames test is rapid and sensitive, however, its usefulness in predicting carcinogenic or mutagenic potential of chemical substances in human is unclear.

In summary, limitations and uncertainties of existing laboratory tests fail to provide an accurate method of examining the effects of a composition on DNA integrity. In view of this, a considerable need exists for screening methodologies which are inexpensive, rapid, and contain the relevant gene from the animal which is to be treated with the composition. Such methods provide a direct assay to determine if a composition interferes with the DNA repair system of a cell.

SUMMARY OF THE INVENTION

The present invention arose from the discovery of a novel protein which is involved in repair of DNA strand breaks. Although this protein has kinase activity, it is the only kinase known to promote repair of DNA strand breaks occurring at a specific nucleotide sequence and allow normal mitotic recombination. The identification of the normal, or "wild-type", protein kinase was made possible by the isolation of a yeast mutant (*hrr25*) defective in repairing DNA strand breaks, but still capable of promoting normal mitotic recombination. The wild-type gene (*HRR25*) was isolated by screening a DNA library for nucleotide sequences which could restore the ability to repair DNA breaks.

A major advantage of the present invention is that it now enables identification of functionally analogous wild-type proteins from other species, especially humans. The identification of such foreign protein provides the further advantage of allowing their use in a screening method designed to examine the effect of various compositions on the DNA break repair promoting activity of the foreign protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1(A) shows the nucleotide and amino acid sequence of the *HRR25* gene. The locations of the prolines and glutamines at the C-terminus are indicated by asterisks and the limits of homology to the protein kinase catalytic domain are shown by arrows. (B) shows the protein kinase homology represented by a shaded region while the P/Q rich region is indicated by cross hatching.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention relates to a DNA recombination and repair gene which can be used in an assay system to examine the effects of various compositions on DNA integrity. The invention also provides a DNA sequence encoding a polypeptide which promotes normal mitotic recombination, but is defective in tyrosine kinase activity and essentially unable to repair DNA strand breaks. This defective DNA sequence is highly useful for identifying other DNA sequences which encode proteins with functional tyrosine kinase activity. These functional sequences, which can be characterized by their ability to restore DNA strand breaks, permit the screening of compositions to determine whether a particular composition has an effect on the restoration of such repair activity. In addition, the present invention relates to the polypeptide encoded by the defective DNA sequence, as well as the polypeptide encoded by the functional wild-type DNA.

In order to identify a DNA sequence encoding a polypeptide with tyrosine kinase activity, a method is provided whereby a DNA library is screened for nucleotide sequences capable of restoring DNA strand break repair in a mutant lacking such activity. A method is further provided for identifying a composition which affects the activity of a mammalian polypeptide having tyrosine kinase activity, wherein the polypeptide is capable of restoring DNA double-strand break repair activity in a mutant lacking such activity.

In general, the defective protein kinase can be characterized by its ability to promote normal mitotic recombination, while being essentially unable to repair DNA double-strand break including that which occurs at the cleavage site:

CAACAG
GTTGTC

The DNA double-strand breaks which the defective protein kinase is essentially unable to repair can be induced by various means, including endonucleases, x-rays, or radiomimetic agents including alkylating agents. Preferred endonucleases are those which recognize the same nucleotide cleavage site as endonuclease *HO*. Radiomimetic alkylating agents having methylmethane sulfonate activity are preferred. Those of skill in the art will be able to identify other agents which induce the appropriate DNA strand breaks without undue experimentation.

The present invention specifically discloses mutants sensitive to continuous expression of the DNA double-strand endonuclease *HO*, which codes for a 65 kDa site-specific endonuclease that initiates mating type interconversion (Kostriken, *et al., Cold Spring Harbor Symp.Quant.Biol.*, 49:89, 1984). These mutants are important to understanding the functions involved in recognizing and repairing damaged chromosomes. This invention also discloses a yeast wild-type DNA recombination and repair gene called *HRR25* (*HO* and/or *r*adiation *r*epair). Homozygous mutant strains, *hrr25-1*, are sensitive to methylmethane sulfonate and X-rays, but not UV irradiation. The wild-type gene encodes a novel protein kinase, homologous to other serine/threonine kinases, which appears critical in activation of DNA repair functions by phosphorylation.

The *HRR25* kinase is important for normal cell growth, nuclear segregation, DNA repair and meiosis, and deletion of *HRR25* results in cell cycle defects. These phenotypes, coupled with the sequence similarities between the *HRR25* kinase and the *Raf/c-mos* protein kinase subgroup suggest that *HRR25* might play a similar role in *S. cerevisiae* growth and development. The defects in DNA strand break repair and the aberrant growth properties revealed by mutations in *HRR25* kinase, expands the role that protein kinases may play and places *HRR25* in a functional category of proteins associated with DNA metabolism.

The development of specific DNA sequences encoding protein kinase polypeptides of the invention can be accomplished using a variety of techniques. For example, methods which can be employed include (1) isolation of a double-stranded DNA sequence from the genomic DNA of the eukaryote; (2) chemical synthesis of a DNA sequence to provide the necessary codons for the polypeptide of interest; and (3) *in vitro* synthesis of a double stranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.

The novel DNA sequences of the invention include all sequences useful in providing for expression in prokaryotic or eukaryotic host cells of polypeptides which exhibit the functional characteristics of the novel protein kinase of the invention. These DNA sequences comprise: (a) the DNA sequences as set forth in Figure 1 or their complementary strands; (b) DNA sequences which encode an amino acid sequence with at least about 35% homology in the protein kinase domain with the amino acid sequences encoded by the DNA sequences defined in (a) or fragments thereof; and (c) DNA sequences defined in (a) and (b) above. Specifically embraced in (b) are genomic DNA sequences which encode allelic variant forms. Part (c)

specifically embraces the manufacture of DNA sequences which encode fragments of the protein kinase and analogs of the protein kinase wherein the DNA sequences thereof may incorporate codons which facilitate translation of mRNA. Also included in part (c) are DNA sequences which are degenerate as a result of the genetic code.

Since the DNA sequence of the invention encodes essentially the entire protein kinase molecule, it is now a routine matter to prepare, subclone, and express smaller polypeptide fragments of DNA from this or a corresponding DNA sequence. The term "polypeptide" denotes any sequence of amino acids having the characteristic activity of the mutant or wild-type protein kinase of the invention, wherein the sequence of amino acids is encoded by all or part of the DNA sequences of the invention.

The polypeptide resulting from expression of the DNA sequence of the invention can be further characterized as being free from association with other eukaryotic polypeptides or other contaminants which might otherwise be associated with the protein kinase in its natural cellular environment.

Isolation and purification of microbially expressed polypeptides provided by the invention may be by conventional means including, preparative chromatographic separations and immunological separations involving monoclonal and/or polyclonal antibody preparation.

In general, expression vectors useful in the present invention contain a promotor sequence which facilitates the efficient transcription of the inserted eukaryotic genetic sequence. The expression vector typically contains an origin of replication, a promoter, and a terminator, as well as specific genes which are capable of providing phenotypic selection of the transformed cells. The transformed hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth. The

polypeptides of the invention can then be isolated from the growth medium, cellular lysates, or cellular membrane fractions.

The DNA sequences of the present invention can be expressed *in vivo* in either prokaryotes or eukaryotes. Methods of expressing DNA sequences containing eukaryotic coding sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors used to incorporate DNA sequences of the invention, for expression and replication in the host cell are well known in the art. For example, DNA can be inserted in yeast using appropriate vectors and introducing the product into the host cells. Various shuttle vectors for the expression of foreign genes in yeast have been reported (Heinemann, *et al., Nature*, 340:205, 1989; Rose, *et al., Gene*, 60:237, 1987). Those of skill in the art will know of appropriate techniques for obtaining gene expression in both prokaryotes and eukaryotes, or can readily ascertain such techniques, without undue experimentation.

Hosts include microbial, yeast and mammalian host organisms. Thus, the term "host" is meant to include not only prokaryotes, but also such eukaryotes such as yeast, filamentous fungi, as well as plant and animal cells which can replicate and express an intron-free DNA sequence of the invention. The term also includes any progeny of the subject cell. It is understood that not all progeny are identical to the parental cell since there may be mutations that occur at replication. However, such progeny are included when the terms above are used.

Transformation with recombinant DNA may be carried out by conventional techniques well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the $CaCl_2$ method using procedures well

known in the art. Alternatively, $MgCl_2$ or RbCl could be used in the reaction. Transformation can also be performed after forming a protoplast of the host cell.

Where the host is a eukaryote, various methods of DNA transfer can be used. These include transfection of DNA by calcium phosphate-precipitates, conventional mechanical procedures such as microinjection, insertion of a plasmid encased in liposomes, spheroplast electroporation, salt mediated transformation of unicellular organisms or the use of virus vectors.

Analysis of eukaryotic DNA has been greatly simplified since eukaryotic DNA can be cloned in prokaryotes using vectors well known in the art. Such cloned sequences can be obtained easily in large amounts and can be altered *in vivo* by bacterial genetic techniques and *in vitro* by specific enzyme modifications. To determine the effects of these experimentally induced changes on the function and expression of eukaryotic genes, the rearranged sequences must be taken out of the bacteria in which they were cloned and reintroduced into a eukaryotic organism. Since there are still many functions in eukaryotic cells which are absent in prokaryotes, (e.g., localization of ATP-generating systems to mitochondria, association of DNA with histones, mitosis and meiosis, and differentiation of cells), the genetic control of such functions must be assessed in a eukaryotic environment. Cloning genes from other eukaryotes in yeast has been useful for analyzing the cloned eukaryotic genes as well as other yeast genes. A number of different yeast vectors have been constructed for this purpose. All vectors replicate in *E. coli*, which is important for amplification of the vector DNA. All vectors contain markers, e.g., LEU 2, HIS 3, URA 3, that can be selected easily in yeast. In addition, these vectors also carry antibiotic resistance markers for use in *E. coli*.

Many strategies for cloning human homologues of known yeast genes are known in the art. These include, but are not limited to: 1) low stringency hybridization to detect shared nucleotide sequences; 2) antibody screening of expression libraries to detect shared structural features; and 3) complementation of mutants to detect genes with similar functions.

For purposes of the present invention, protein kinases which are homologous can be identified by structural as well as functional similarity. Structural similarity can be determined, for example, by assessing amino acid homology or by screening with antibody, especially a monoclonal antibody, which recognizes a unique epitope present on the protein kinases of the invention. When amino acid homology is used as criteria to establish structural similarity, those amino acid sequences which have homology of at least about 35% in the protein kinase domain are considered to be essentially the same as the amino acid sequences of the invention.

When homologous amino acid sequences are evaluated based on functional characteristics, then a homologous amino acid sequence is considered equivalent to the amino acid sequence of the invention when the homologous sequence is essentially unable to repair (in the case of the repair defective mutant gene) or able to repair (in the case of the natural gene), DNA double-strand breaks, including that which occurs at a nucleotide cleavage site

CAACAG
GTTGTC

and when the homologous amino acid sequence allows normal mitotic recombination.

This invention preferably uses the functional screening method whereby genes are cloned from plasmid libraries by complementation of a recessive

marker. A recipient strain such as *Saccharomyces cerevisiae* is constructed that carries a recessive mutation in the gene of interest. This strain is then transformed with a plasmid, for example, pYES2 (Invitrogen, San Diego, CA) containing the wild-type genomic DNA or cDNA. The clone carrying the gene of interest can then be selected by replica plating to a medium that distinguishes mutant from wild-type phenotypes for the gene of interest. The plasmid can then be extracted from the clone and the DNA studied. Several yeast vectors allow the application of complementation systems to go beyond isolation of yeast genes. Genes from a wide variety of species can be isolated using these vectors. In such systems, DNA sequences from any source are cloned into a vector and can be screened directly in yeast for activities that will complement specific yeast mutations.

In a preferred embodiment, the present invention uses a mutation in yeast, the *hrr25* mutation, which was identified by sensitivity to DNA double-strand breaks induced by the HO endonuclease. The genomic DNA which complements this mutation was isolated by transforming the *hrr25* strain with a DNA library and subsequently screening for methylmethane sulfonate (MMS) resistance. Alternately, functional genes from a variety of mammalian species can now be cloned using the system described.

Yeast genes can be cloned by a variety of techniques, including use of purified RNA as hybridization probes, differential hybridization of regulated RNA transcripts, antibody screening, transposon mutagenesis, cross suppression of mutant phenotypes, cross hybridization with heterologous cDNA or oligonucleotide probes, as well as by complementation in *E. coli*.

Minor modifications of the primary amino acid sequence may result in proteins which have substantially equivalent or enhanced activity as compared to the sequence set forth in Figure 1. The modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous by

HRR25 producing organisms. All of these modifications are included in the invention as long as *HRR25* activity is retained. Substitution of an aspartic acid residue for a glycine acid residue at position 151 in the sequence shown in FIGURE 1 identifies the mutant *hrr25*.

Antibodies provided by the present invention are immunoreactive with the mutant polypeptides and/or the naturally occurring protein kinase. Antibody which consist essentially of numerous monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided. Monoclonal antibody is made from antigen containing fragments of the polypeptide by methods well known in the art (Kohler,G. *et al.*, *Nature* 256:495, 1975; *Current Protocols in Molecular Biology*, Ausubel, F. *et al.*, ed.,1989).

The invention also discloses a method for identifying a composition which affects the activity of a polypeptide having tyrosine kinase activity. The polypeptide is capable of restoring DNA double-strand break repair activity in host cells containing the *hrr25* gene. The composition and the polypeptide are incubated in combination with host cells for a period of time and under conditions sufficient to allow the components to interact, then subsequently monitoring the change in tyrosine kinase activity, for example, by decreased repair of DNA double-strand breaks. The DNA strand breaks are induced, for example, by a radiomimetic agent, such as methylmethane sulfonate, x-rays, or by endonuclease like *HO*. Other means of inducing double-strand breaks that are well known in the art may be employed as well.

The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.

EXAMPLE 1

ISOLATION OF *hrr25*

S. cerevisiae strain K264-5B (*MATα ho ura3 can1^R tyr1 his7 lys2 ade5 met13 trp5 leu1 ade5*) was employed for the mutant isolation. The yeast were transformed according to standard procedures with a *URA3*-based integrating plasmid that contained a *GAL1,10*-regulated *HO* endonuclease and a transformant was mutagenized to approximately 50% survival with ethyl methanesulfonate (EMS), as described (*Current Protocols in Molecular Biology, supra*). The culture was spread onto glycerol-containing rich medium (YPG, to avoid petites), colonies were allowed to form at 30°C, and plates were replicated to glucose (*HO* repressing) and galactose (*HO* inducing) media. Mutants were identified by their inability to grow on galactose. Approximately 200 mutants were chosen for initial characterization and 62 maintained the *gal-* phenotype through repeated single colony purification. Among these, many were not complemented by various *gal* mutants. The remainder (25 mutants) were surveyed for overlapping DNA repair defects by determining sensitivity to ultraviolet (UV) irradiation and to methyl methane sulfonate (MMS). This screening method identified five alleles of known *rad* mutations and one new mutation. This new mutation *hrr25-1* (*H*O and/or *r*adiation *r*epair), presented severe defects and was studied further.

A recessive DNA repair defect is conferred by *hrr25-1* that includes sensitivity to MMS. *Hrr25-1* strains also show sensitivity at 5-20 Krad X-irradiation similar to that observed with mutations in the radiation repair genes *RAD50* and *RAD52* (Cole, *et al., Mol.Cell.Biol.*, 9:3101, 1989). The *hrr25-1* strains are no more sensitive to UV irradiation than wild type and are not temperature sensitive for growth at 37°C. Unlike hypo- and hyper-rec *rad* mutants which have several of the *hrr25-1* phenotypes, *hrr25-1* strains

undergo normal mitotic recombination (Cole, *et al., Mol.Cell.Biol.*, 9:3101, 1989). Spontaneous gene conversion and crossing-over were the same for homozygous *hrr25-1* and wild type strains. However, *HRR25* is required for the correct completion of meiosis. The *hrr25-1* homozygotes showed less than 1% spores (tetranucleate cells) under conditions that produced 75-80% spores in an isogenic wild type strain. The *hrr25-1* mutation could be complemented by a number of radiation sensitive mutations (*rad6, 50, 52, 54, and 57*) that present some of the *hrr25* phenotypes, suggesting that *hrr25-1* is a newly uncovered *rad*-like mutation and not one of these previously described genes. These results also indicate that *HRR25* plays a role in DNA repair and meiosis, but is not specifically required for the repair of spontaneous mitotic lesions by recombination.

EXAMPLE 2

ISOLATION OF *HRR25*

The *HRR25* gene was obtained by complementing for MMS sensitivity using a yeast genomic library constructed in the plasmid YCp50 (Rose, *et al., Gene*, 60:237, 1987). An *hrr25-1* strain, MHML 3-36d (ura3 *hrr25*), was transformed by standard methods (Nickoloff, *et al., J.Mol.Biol.*, 207:527, 1989) to uracil prototrophy, transformants were amplified on media without uracil and replicated to media containing 0.01% MMS. Among 1200 transformants, a single MMS resistant isolate was identified. Complementation for MMS sensitivity was found to segregate with the plasmid as determined by methods known in the art.

A 12 kb genomic fragment was identified and complementing activity was localized to a 3.1 kb *Bam*HI-*Sal*I fragment by transposon mutagenesis and subcloning. This region complemented DNA repair defects as well as meiotic deficiencies. Gene targeting experiments linked this cloned region

to *hrr25-1*. Transposon insertion mutations within the *Bam*HI-*Sal*I fragment replaced into the cognate *HRR25* genomic locus did not complement *hrr25-1* for MMS sensitivity, whereas adjacent chromosomal insertions outside the complementing region segregated in repulsion when crossed against *hrr25-1*.

Mini-Tn*10LUK* transposons (Huisman, *et al., Genetics*, 116:191, 1987) were used to delineate the approximate location of *HRR25* on the 12 kb *Bam*HI-*Sal*I fragment. Insertions located to the left hand 9 kb (of the 12 kb genomic fragment) did not inactivate complementation of *hrr25-1* MMS resistance compared with the un-mutagenized plasmid. Two insertions, located near an *Eco*RV site in the right hand 2 kb inactivated complementation. *HRR25* complementation activity was localized to a 3.4 kb *Sal*I fragment. Approximately 300 bp of this fragment (right hand side of the 12 kb) were part of the pBR322 tetracycline resistance gene (between the *Bam*HI site of pBR322-based YCp50). The *HRR25* open reading frame spans an internal region across an *Eco*RV site and two *Bgl*II sites within the right terminal 3 kb.

The DNA sequence of the 3.1 kb fragment revealed a centrally located open reading frame of 1482 nucleotide. A transposon insertion mutation in this open reading frame inactivated *HRR25* complementation whereas insertions elsewhere in the 12 kb clone did not affect *HRR25* complementation. Transposon-mediated disruption of *HRR25* also revealed several phenotypes not seen with *hrr25-1*. As expected, a Tn*10*-based LUK transposon insertion (Huisman, *et al., Genetics*, 116:191, 1987) into the middle of plasmid-borne *HRR25* coding region inactivated complementation for MMS sensitivity. Transplacement of this insertion into the genomic *HRR25* gene revealed a severe growth defect in addition to MMS sensitivity and meiotic inviability. This severe growth defect was not observed with *hrr25-1* strains. Wild type *HRR25* strains doubled in rich media at 30°C every 80-90 minutes whereas

isogenic *hrr25::LUK* strains and *hrr25Δ* doubled every 9-12 hours. *hrr25-1* had a doubling time of 2-4 hours.

To determine whether the mutant phenotypes revealed by the *hrr::LUK* disruption allele represent a null phenotype, the entire *HRR25* coding sequence was deleted. Briefly, deletion of the *HRR25* coding sequence employed a *hisG::URA3::hisG* cassette (Alani, *et al.*, *Genetics*, 116:541, 1988). The 3.1 kb *HRR25 Sal*I fragment was cloned into pBluescript (Stratagene, La Jolla, CA). This plasmid was digested with *Bgl*II and the two *Bgl*II fragments that span the entire *HRR25* gene and its flanking sequences were deleted. Into this deletion was introduced the 3.8kb BamHI-*Bgl*II *hisG::URA3::hisG* fragment from pNKY51 to create the *hrr25Δ* allele. *Sal*I digestion yielded a linearized fragment that deleted the entire *HRR25* locus. Yeast carrying the deletion-disruption allele (*hrr25Δ*) showed phenotypes identical to those with the *hrr25::LUK* allele for all properties examined, including MMS sensitivity, slow growth, and the sporulation defect, indicating that wild-type *HRR25* protein is associated with these processes and that the *hrr25::LUK* allele does not indirectly interfere with DNA repair, growth or sporulation. In direct parallel comparisons, the *hrr25::LUK* and *hrr25Δ* alleles behaved identically.

Yeast strain MFH14 (*MATa/MATα ura3/ura3*) was transformed with *Bgl*II-linearized YCp50-*HRR25*::LUK to uracil prototrophy, heterozygous disruption of *HRR25* was verified by Southern blot analysis, the diploid was sporulated by starvation for nitrogen and fermentable carbon source, tetrads dissected and cells allowed to germinate at 30°C for 7 days. After a normal germination period of 2 days, the severe growth defect of *hrr25*::LUK suggested that the deletion of *HRR25* was lethal. However, microscopic examination of segregants revealed that *hrr25*::LUK germinating cells grew slowly and in every case examined (20/20 tetrads), slow growth, MMS sensitivity, and uracil prototrophy co-segregated. A color variation was seen

seen with diploid MFH14 segregants, due to mutations in adenine biosynthesis. MFH14 is *ade5/ADE5 ade2/ade2*. An *ade5/ade2* strain was white, while an *ADE5/ade2* strain was red.

EXAMPLE 3

SEQUENCE AND STRUCTURE OF THE *HRR25* GENE

DNA sequencing of both strands of the *HRR25* gene was done by uni-directional deletions employing Sequenase (USB, Cleveland, OH) and Exo-Meth (Stratagene, La Jolla, CA) procedures as described by the manufacturers. Figure 1A, shows the location of the prolines and glutamines at the C-terminus as indicated by asterisks, and the limits of homology to protein kinase catalytic domains. Figure 1B shows a schematic representation of the structure of *HRR25*. The protein kinase homology is represented by a shaded region while the P/Q rich region is indicated by cross-hatchings. The mutant, *hrr25*, can be distinguished from *HRR25* by one amino acid substitution. At position 151, an aspartic acid is substituted for glycine.

The predicted translation product of *HRR25* revealed an unexpected feature for a *rad*-like DNA repair function. *HRR25* contains the hallmark signatures of sequence homology with the catalytic domain of serine/threonine protein kinase superfamily members (Hanks, *et al.*, *Science*, 241:42, 1988). For comparison, the *HRR25* translation product was aligned with the catalytic domains for two subgroups of yeast protein kinases, the *CDC28/cdc2* group and the *KSS1/FUS3* group. Located between amino acids 15 and 30 is a region that contains the conserved GXGXXG region. Just C-terminal to this region is a conserved lysine and glutamic acid present in most known kinases. These regions are thought to function in the nucleotide binding

and phosphotransfer steps of the kinase reaction (Hanks, *et al., Science*, 241:42,1988). Between amino acid residues 120 to 150 are regions containing the HRD and DFG motifs, also found in most protein kinase family members. In addition, sequence examination of all known serine/threonine kinases indicates that *HRR25* shares some additional similarities with the *Raf/PKS/mos* subgroup (Hanks, *et al., Science*, 241:42, 1988). The strongest homologies can be found in areas around the GXGXXG, DFG, and DXXSXG conserved regions in protein kinase catalytic domains.

The functional relevance of the observed sequence similarity between *HRR25* and protein kinases was studied by altering specific residues within the *HRR25* kinase domain and examining the phenotypic consequences of these changes. A lysine at position 38 (Lys ^{38}) was mutated to an arginine residue by site directed mutagenesis, by methods known in the art. The mutagenic oligonucleotide was:

5'-CCTGATCGATTCCAGCCTGATCGCTACTTCTTCACCACT-3'.

Lys^{38} in *HRR25* corresponds to the lysine found in all known protein kinases, and this subdomain is involved in ATP binding. Mutations at the conserved lysine in protein kinases such as *v-src, v-mos, and DBF2* inactivate these proteins. The mutant *hrr25*-Lys^{38} allele was incapable of complementing *hrr25-1*, *hrr25::LUK*, and *hrr25*Δ alleles for all properties examined, an indication that the *HRR25* kinase domain is required for *in vivo* function of *HRR25*.

The predicted *HRR25* translation product has a number of notable features outside the region of homology to protein kinase catalytic domains. For example, the last 100 amino acids is proline and glutamine rich, containing 50 of these residues. Other proteins with regions rich in these two amino

acids include the transcription factors *Sp1*, *jun*, and *HAP2*, steroid hormone receptors, the *S. pombe ran1* kinase, and *mak*-male germ cell-associated kinase (Courey, *et al.*, *Cell*, 55:887, 1988; Bohmann, *et al.*, *Science*, 238:1386, 1987; Roussou, *et al.*, *Mol.Cell.Biol.*, 8:2132, 1988; Arriza, *et al.*, *Science*, 237:268, 1987; Matsushime, *et al.*, *Mol.Cell.Biol.*, 10:2261, 1990). In the case of *Sp1* and *jun*, the proline-glutamine regions are involved in transactivation, whereas the P/Q region in the human mineralocorticoid receptor is thought to serve as an intramolecular bridge. This proline-glutamine region in *HRR25* might function as a structural feature for substrate interaction, or for subcellular localization. Also, the glutamine richness of this region is similar to the *opa* or M-repeat seen in the *Drosophila* and *Xenopus Notch/Xotch* proteins (Wharton, *et al.*, *Cell*, 40:55, 1985; Coffman, *et al.*, *Science*, 249:1438, 1990). The function of the *opa* repeat is not certain, but it is found in several *Drosophila* genes. Lastly, the sequence TKKQKY at the C-terminal end of the region homologous to protein kinases is similar to the nuclear localizing signal of SV40 large T antigen and yeast histone H2B (Silver, *et al.*, *J.Cell.Biol.*, 109:983, 1989; Moreland, *et al.*, *Mol.Cell.Biol.*, 7:4048, 1987).

EXAMPLE 4

MICROSCOPIC ANALYSIS OF GERMINATING AND PROLIFERATING *hrr25* CELLS

Photomicrographs of *HRR25* and *hrr25::LUK* colonies were taken after germination on rich medium. An MFH14 *hrr25::LUK* heterozygous transformant was dissected onto a thin film of YPD rich medium on a sterilized microscope slide and segregants were allowed to germinate under a coverslip by incubating the slide in a moist 30°C chamber. Photographs of colonies were taken after 2 days of growth. Phase contrast and DAPI staining of proliferating *HRR25*Δ and *hrr25::LUK* cells were compared. Cells

were inoculated into YPD rich medium and grown at 30°C to a mid-log density of 1-3 X 10^7 cells/ml, briefly sonicated to disrupt clumps, fixed with formaldehyde, and stained with DAPI (Williamson, *et al., Meth.Cell.Biol.*, 12:335, 1975). Many cells with *hrr25::LUK* lacked DAPI stainable nuclei.

Microscopic examination of germinating and actively growing mid-log phase *hrr25::LUK* cells revealed aberrant cellular morphologies. Transposon disruption of *HRR25* resulted in large cells, and 25-40% of cells were filamentous or extended. DAPI nuclear staining (Williamson, *et al., Meth.Cell.Biol.*, 12:335, 1975) of mid-log populations showed that orderly cell cycle progression in *hrr25* mutants was lost. There were a large number of cells lacking DAPI-stainable nuclei which, by single cell manipulations proved to be inviable. Consistent with this nuclear segregation defect, the plating efficiency of *hrr25::LUK* haploids was also reduced to 75-80% of wild type. However, this reduction in plating efficiency is insufficient to account for the severe growth rate reduction. Plating efficiency was measured from mid-log phase cells by comparing the efficiency of colony formation on rich medium relative to the total number of cells determined by hemocytometer count. Cell populations were analyzed for DNA content distribution by flow cytometric analysis following staining with propidium iodide as described (Hutter, *et al. J.Gen.Microbiol.*, 113:369, 1979). Cell sorting analysis showed that a large number of the cells in a haploid *hrr25::LUK* population were delayed in the cell cycle and exhibited G2 DNA content, but the population was not arrested uniformly in the cell cycle.

EXAMPLE 5

SEQUENCE COMPARISON OF *HRR25* WITH *CDC28, KSS1,* AND *RAF1*

The predicted translation product of *HRR25* was compared with the catalytic domains of several members of the serine/threonine protein kinase superfamily. Initial sequence comparisons employed the UWGCG programs (Devereux, *et al., Nuc.Acids.Res.*, 12:387, 1984), whereas subgroup comparisons used the methods of Hanks, *et al., supra*. *HRR25* contains all eleven subdomains described by Hanks, *et al., supra*. Structurally similar groupings were compared in the sequence comparisons. These included nonpolar chain R groups, aromatic or ring-containing R groups, small R groups with near neutral polarity, acidic R groups, uncharged polar R groups, and basic polar R groups.

CDC28 and *KSS1* represent members of two subgroups of serine/threonine protein kinases in yeast. *CDC28* is involved in cell cycle regulation while *KSS1* acts in the regulation of the yeast mating pathway. *HRR25* shows 21% identity and 41% similarity to *CDC28* and 19% identity and 43% similarity to *KSS1*. *HRR25* shows highest similarity to members of the *Raf1/PKS/Mos* family of protein kinases. Through the catalytic domain, *HRR25* shows 30% identity and 49% similarity to *Raf1*.

SUMMARY OF SEQUENCES

Sequence I.D. No. 1 is the nucleic acid sequence (and the deduced amino acid sequence) of a genomic fragment encoding a yeast-derived tyrosine kinase of the present invention.

Sequence I.D. No. 2 is the deduced amino acid sequence of a yeast-derived tyrosine of the present invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Hoekstra, Merl F.

(ii) TITLE OF INVENTION: TYROSINE KINASE

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Spensley Horn Jubas & Lubitz
(B) STREET: 4225 Executive Square, Suite 1400
(C) CITY: La Jolla
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 92037

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE: 03-JUL-1991
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Wetherell Ph.D., John R.
(B) REGISTRATION NUMBER: 13,678
(C) REFERENCE/DOCKET NUMBER: PD-1318

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (619) 455-5100
(B) TELEFAX: (619) 455-5110

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3098 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vii) IMMEDIATE SOURCE:
(B) CLONE: Tyrosine Kinase

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 879..2364

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTCGACTCGC CAATCACCAA GTTCTTATCC CACATCCGAC CAGTGTCTGA GTCATGGTTT 60

ACCACCACCA TACCATCGCT GGTCATTTGT AAATCCGTTT CTATTACATC AGCACCTGCT 120

GCATAAGCCT TCTCAAATGC TAGTAGCGTA TTTTCAGGAT ATCTTGCTTT AAAAGCTCTG 180

TGGCCCACAA TTTCAACCAT CCTCGTGTCC TTGTTGTTAT CTTACACTTC TTATTTATCA 240

ATAACACTAG TAACATCAAC AACACCAATT TTATATCTCC CTTAATTGTA TACTAAAAGA 300

TCTAAACCAA TTCGGTATTG TCCTCGATAC GGCATGCGTA TAAAGAGATA TAATTAAAAG 360

AGGTTATAGT CACGTGATGC AGATTACCCG CAACAGTACC ACAAAATGGA TACCATCTAA 420

TTGCTATAAA AGGCTCCTAT ATACGAATAA CTACCACTGG ATCGACGATT ATTTCGTGGC 480

AATCATATAC CACTGTGAAG AGTTACTGCA ACTCTCGCTT TGTTTCAACG CTTCTTCCCG 540

TCTGTGTATT TACTACTAAT AGGCAGCCCA CGTTTGAATT TCTTTTTTTC TGGAGAATTT 600

TTGGTGCAAC GAGGAAAAGG AGACGAAGAA AAAAAGTTGA AACACGACCA CATATATGGA 660

ACGTGGTTGA AATACAAAGA GAAGAAAGGT TCGACACTCG AGGAAAGCAT TTGGTGGTGA 720

AAACACATCT TAGTAGCATC TTTAAACCTC TGTTGGGTAC TTAGAAAAAT ATTTCCAGAC 780

TTCAAGGATA AAAAAAGTCG AAAAGTTACG ACATATTCGA CCAAAAAAAA AAACCAAAAA 840

```
GAAAAGATAT ATTTATAGAA AGGATACATT AAAAAGAG ATG GAC TTA AGA GTA          893
                                          Met Asp Leu Arg Val
                                           1               5

GGA AGG AAA TTT CGT ATT GGC AGG AAG ATT GGG AGT GGT TCC TTT GGT          941
Gly Arg Lys Phe Arg Ile Gly Arg Lys Ile Gly Ser Gly Ser Phe Gly
                10                  15                  20

GAC ATT TAC CAC GGC ACG AAC TTA ATT AGT GGT GAA GAA GTA GCC ATC          989
Asp Ile Tyr His Gly Thr Asn Leu Ile Ser Gly Glu Glu Val Ala Ile
            25                  30                  35

AAG CTG GAA TCG ATC AGG TCC AGA CAT CCT CAA TTG GAC TAT GAG TCC         1037
Lys Leu Glu Ser Ile Arg Ser Arg His Pro Gln Leu Asp Tyr Glu Ser
        40                  45                  50

CGC GTC TAC AGA TAC TTA AGC GGT GGT GTG GGA ATC CCG TTC ATC AGA         1085
Arg Val Tyr Arg Tyr Leu Ser Gly Gly Val Gly Ile Pro Phe Ile Arg
    55                  60                  65

TGG TTT GGC AGA GAG GGT GAA TAT AAT GCT ATG GTC ATC GAT CTT CTA         1133
Trp Phe Gly Arg Glu Gly Glu Tyr Asn Ala Met Val Ile Asp Leu Leu
70                  75                  80                  85

GGC CCA TCT TTG GAA GAT TTA TTC AAC TAC TGT CAC AGA AGG TTC TCC         1181
Gly Pro Ser Leu Glu Asp Leu Phe Asn Tyr Cys His Arg Arg Phe Ser
                90                  95                  100

TTT AAG ACG GTT ATC ATG CTG GCT TTG CAA ATG TTT TGC CGT ATT CAG         1229
Phe Lys Thr Val Ile Met Leu Ala Leu Gln Met Phe Cys Arg Ile Gln
            105                 110                 115
```

```
TAT ATA CAT GGA AGG TCG TTC ATT CAT AGA GAT ATC AAA CCA GAC AAC      1277
Tyr Ile His Gly Arg Ser Phe Ile His Arg Asp Ile Lys Pro Asp Asn
        120                 125                 130

TTT TTA ATG GGG GTA GGA CGC CGT GGT AGC ACC GTT CAT GTT ATT GAT      1325
Phe Leu Met Gly Val Gly Arg Arg Gly Ser Thr Val His Val Ile Asp
    135                 140                 145

TTC GGT CTA TCA AAG AAA TAC CGA GAT TTC AAC ACA CAT CGT CAT ATT      1373
Phe Gly Leu Ser Lys Lys Tyr Arg Asp Phe Asn Thr His Arg His Ile
150                 155                 160                 165

CCT TAC AGG GAG AAC AAG TCC TTG ACA GGT ACA GCT CGT TAT GCA AGT      1421
Pro Tyr Arg Glu Asn Lys Ser Leu Thr Gly Thr Ala Arg Tyr Ala Ser
                170                 175                 180

GTC AAT ACG CAT CTT GGA ATA GAG CAA AGT AGA AGA GAT GAC TTA GAA      1469
Val Asn Thr His Leu Gly Ile Glu Gln Ser Arg Arg Asp Asp Leu Glu
            185                 190                 195

TCA CTA GGT TAT GTC TTG ATC TAT TTT TGT AAG GGT TCT TTG CCA TGG      1517
Ser Leu Gly Tyr Val Leu Ile Tyr Phe Cys Lys Gly Ser Leu Pro Trp
        200                 205                 210

CAG GGT TTG AAA GCA ACC ACC AAG AAA CAA AAG TAT GAT CGT ATC ATG      1565
Gln Gly Leu Lys Ala Thr Thr Lys Lys Gln Lys Tyr Asp Arg Ile Met
    215                 220                 225

GAA AAG AAA TTA AAC GTT AGC GTG GAA ACT CTA TGT TCA GGT TTA CCA      1613
Glu Lys Lys Leu Asn Val Ser Val Glu Thr Leu Cys Ser Gly Leu Pro
230                 235                 240                 245
```

```
TTA GAG TTT CAA GAA TAT ATG GCT TAC TGT AAG AAT TTG AAA TTC GAT      1661
Leu Glu Phe Gln Glu Tyr Met Ala Tyr Cys Lys Asn Leu Lys Phe Asp
                250                 255                 260

GAG AAG CCA GAT TAT TTG TTC TTG GCA AGG CTG TTT AAA GAT CTG AGT      1709
Glu Lys Pro Asp Tyr Leu Phe Leu Ala Arg Leu Phe Lys Asp Leu Ser
            265                 270                 275

ATT AAA CTA GAG TAT CAC AAC GAC CAC TTG TTC GAT TGG ACA ATG TTG      1757
Ile Lys Leu Glu Tyr His Asn Asp His Leu Phe Asp Trp Thr Met Leu
        280                 285                 290

CGT TAC ACA AAG GCG ATG GTG GAG AAG CAA AGG GAC CTC CTC ATC GAA      1805
Arg Tyr Thr Lys Ala Met Val Glu Lys Gln Arg Asp Leu Leu Ile Glu
    295                 300                 305

AAA GGT GAT TTG AAC GCA AAT AGC AAT GCA GCA AGT GCA AGT AAC AGC      1853
Lys Gly Asp Leu Asn Ala Asn Ser Asn Ala Ala Ser Ala Ser Asn Ser
310                 315                 320                 325

ACA GAC AAC AAG TCT GAA ACT TTC AAC AAG ATT AAA CTG TTA GCC ATG      1901
Thr Asp Asn Lys Ser Glu Thr Phe Asn Lys Ile Lys Leu Leu Ala Met
                330                 335                 340

AAG AAA TTC CCC ACC CAT TTC CAC TAT TAC AAG AAT GAA GAC AAA CAT      1949
Lys Lys Phe Pro Thr His Phe His Tyr Tyr Lys Asn Glu Asp Lys His
            345                 350                 355

AAT CCT TCA CCA GAA GAG ATC AAA CAA CAA ACT ATC TTG AAT AAT AAT      1997
Asn Pro Ser Pro Glu Glu Ile Lys Gln Gln Thr Ile Leu Asn Asn Asn
        360                 365                 370
```

```
GCA GCC TCT TCT TTA CCA GAG GAA TTA TTG AAC GCA CTA GAT AAA GGT      2045
Ala Ala Ser Ser Leu Pro Glu Glu Leu Leu Asn Ala Leu Asp Lys Gly
    375                 380                 385

ATG GAA AAC TTG AGA CAA CAG CAG CCG CAG CAG CAG GTC CAA AGT TCG      2093
Met Glu Asn Leu Arg Gln Gln Gln Pro Gln Gln Gln Val Gln Ser Ser
390                 395                 400                 405

CAG CCA CAA CCA CAG CCC CAA CAG CTA CAG CAG CAA CCA AAT GGC CAA      2141
Gln Pro Gln Pro Gln Pro Gln Gln Leu Gln Gln Gln Pro Asn Gly Gln
                410                 415                 420

AGA CCA AAT TAT TAT CCT GAA CCG TTA CTA CAG CAG CAA CAA AGA GAT      2189
Arg Pro Asn Tyr Tyr Pro Glu Pro Leu Leu Gln Gln Gln Gln Arg Asp
            425                 430                 435

TCT CAG GAG CAA CAG CAG CAA GTT CCG ATG GCT ACA ACC AGG GCT ACT      2237
Ser Gln Glu Gln Gln Gln Gln Val Pro Met Ala Thr Thr Arg Ala Thr
        440                 445                 450

CAG TAT CCC CCA CAA ATA AAC AGC AAT AAT TTT AAT ACT AAT CAA GCA      2285
Gln Tyr Pro Pro Gln Ile Asn Ser Asn Asn Phe Asn Thr Asn Gln Ala
    455                 460                 465

TCT GTA CCT CCA CAA ATG AGA TCT AAT CCA CAA CAG CCG CCT CAA GAT      2333
Ser Val Pro Pro Gln Met Arg Ser Asn Pro Gln Gln Pro Pro Gln Asp
470                 475                 480                 485

AAA CCA GCT GGC CAG TCA ATT TGG TTG TAA G CAACATATAT TGCTCAAAAC      2384
Lys Pro Ala Gly Gln Ser Ile Trp Leu  *
                490                 495
```

GCACAAAAAT AAACATATGT ATATATAGAC ATACACACAC ACATATATAT ATATATATTA 2444

TTATTATTAT TTACATATAC GTACACACAA TTCCATATCG AGTTAATATA TACAATTCTG 2504

GCCTTCTTAC CTAAAAAGAT GATAGCTAAA AGAACCACTT TTTTTATGCA TTTTTTTCTT 2564

CGGGAAGGAA ATTAAGGGGG AGCGGAGCAC CTCTTGGCCA ATTTGTTTTT TTTTTATGTA 2624

ATAAAGGGCT AACGATCGAA GATCAATCAC GAATATTGGA CGGTTTTAAA GGAGGGCCTC 2684

TGAGAAGACA GCATCAATTC GTATTTTCGA TAATTAACTT GCCTTATAGT GTCTGATTAG 2744

GAAACAATCA CGAGACGATA ACGACGGAAT ACCAAGGAAG TTTGTGCAAA TATACAGCCG 2804

GCACAAACAG CAGCTTCACT CAGGTTAACT CACATACTGT TGAAAATTGT CGGTATGGAA 2864

TTCGTTGCAG AAAGGGCTCA GCCAGTTGGT CAAACAATCC AGCAGCAAAA TGTTAATACT 2924

TACGGGCAAG GCGTCCTACA ACCGCATCAT GATTTACAGC AGCGACAACA ACAACAACAG 2984

CAGCGTCAGC ATCAACAACT GCTGACGTCT CAGTTGCCCC AGAAATCTCT CGTATCCAAA 3044

GGCAAATATA CACTACATGA CTTCCAGATT ATGAGAACGC TTGGTACTGG ATCC 3098

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 495 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asp Leu Arg Val Gly Arg Lys Phe Arg Ile Gly Arg Lys Ile Gly
1 5 10 15

Ser Gly Ser Phe Gly Asp Ile Tyr His Gly Thr Asn Leu Ile Ser Gly
20 25 30

Glu Glu Val Ala Ile Lys Leu Glu Ser Ile Arg Ser Arg His Pro Gln
35 40 45

Leu Asp Tyr Glu Ser Arg Val Tyr Arg Tyr Leu Ser Gly Gly Val Gly
50 55 60

Ile Pro Phe Ile Arg Trp Phe Gly Arg Glu Gly Glu Tyr Asn Ala Met
65 70 75 80

Val Ile Asp Leu Leu Gly Pro Ser Leu Glu Asp Leu Phe Asn Tyr Cys
85 90 95

His Arg Arg Phe Ser Phe Lys Thr Val Ile Met Leu Ala Leu Gln Met
100 105 110

Phe Cys Arg Ile Gln Tyr Ile His Gly Arg Ser Phe Ile His Arg Asp
115 120 125

Ile Lys Pro Asp Asn Phe Leu Met Gly Val Gly Arg Arg Gly Ser Thr
130 135 140

Val His Val Ile Asp Phe Gly Leu Ser Lys Lys Tyr Arg Asp Phe Asn
145 150 155 160

Thr His Arg His Ile Pro Tyr Arg Glu Asn Lys Ser Leu Thr Gly Thr
165 170 175

Ala Arg Tyr Ala Ser Val Asn Thr His Leu Gly Ile Glu Gln Ser Arg
180 185 190

Arg Asp Asp Leu Glu Ser Leu Gly Tyr Val Leu Ile Tyr Phe Cys Lys
195 200 205

Gly Ser Leu Pro Trp Gln Gly Leu Lys Ala Thr Thr Lys Lys Gln Lys
210 215 220

Tyr Asp Arg Ile Met Glu Lys Lys Leu Asn Val Ser Val Glu Thr Leu
225 230 235 240

Cys Ser Gly Leu Pro Leu Glu Phe Gln Glu Tyr Met Ala Tyr Cys Lys
245 250 255

Asn Leu Lys Phe Asp Glu Lys Pro Asp Tyr Leu Phe Leu Ala Arg Leu
260 265 270

Phe Lys Asp Leu Ser Ile Lys Leu Glu Tyr His Asn Asp His Leu Phe
275 280 285

Asp Trp Thr Met Leu Arg Tyr Thr Lys Ala Met Val Glu Lys Gln Arg
290 295 300

Asp Leu Leu Ile Glu Lys Gly Asp Leu Asn Ala Asn Ser Asn Ala Ala
305 310 315 320

Ser Ala Ser Asn Ser Thr Asp Asn Lys Ser Glu Thr Phe Asn Lys Ile
325 330 335

Lys Leu Leu Ala Met Lys Lys Phe Pro Thr His Phe His Tyr Tyr Lys
340 345 350

Asn Glu Asp Lys His Asn Pro Ser Pro Glu Glu Ile Lys Gln Gln Thr
355 360 365

Ile Leu Asn Asn Asn Ala Ala Ser Ser Leu Pro Glu Glu Leu Leu Asn
370 375 380

Ala Leu Asp Lys Gly Met Glu Asn Leu Arg Gln Gln Gln Pro Gln Gln
385 390 395 400

Gln Val Gln Ser Ser Gln Pro Gln Pro Gln Pro Gln Gln Leu Gln Gln
405 410 415

Gln Pro Asn Gly Gln Arg Pro Asn Tyr Tyr Pro Glu Pro Leu Leu Gln
420 425 430

Gln Gln Gln Arg Asp Ser Gln Glu Gln Gln Gln Gln Val Pro Met Ala
435 440 445

Thr Thr Arg Ala Thr Gln Tyr Pro Pro Gln Ile Asn Ser Asn Asn Phe
450 455 460

```
Asn Thr Asn Gln Ala Ser Val Pro Pro Gln Met Arg Ser Asn Pro Gln
465                 470                 475                 480

Gln Pro Pro Gln Asp Lys Pro Ala Gly Gln Ser Ile Trp Leu  *
                485                 490                 495
```

The invention now being fully described, it will be apparent to one of ordinary skill in the art that various changes and modifications can be made without departing from the spirit or scope of the invention.

CLAIMS

1. A DNA sequence encoding a polypeptide with defective tyrosine kinase activity, wherein the polypeptide is characterized as:

   (a) promoting normal mitotic recombination; and

   (b) being essentially unable to repair a DNA double-strand break which occurs at the cleavage site:



2. The DNA sequence of claim 1, wherein the break is induced by an endonuclease.

3. The DNA sequence of claim 2, wherein the endonuclease is *HO*.

4. The DNA sequence of claim 1, selected from the group consisting of:

   (a) cDNA having a nucleotide sequence derived from the genomic coding region of the polypeptide;

   (b) DNA sequences encoding an amino acid sequence having at least about 35% homology in the protein kinase domain with the amino acid sequence encoded by the cDNA of (a); and

   (c) DNA sequences which are degenerate as a result of the genetic code with respect to the DNA sequences of (a) and (b).

5. The DNA sequence of claim 1 which is *hrr25* gene.

6. The DNA sequence of claim 1, wherein the DNA sequence is derived from a yeast.

7. A host cell containing the DNA sequence of claim 1.

8. The host cell of claim 7 wherein the DNA sequence is introduced by transformation or transfection.

9. A biologically functional plasmid or viral DNA vector comprising the DNA sequence of claim 1.

10. A functional polypeptide encoded by all or a portion of the DNA sequence of claim 1.

11. A polypeptide with defective tyrosine kinase activity, wherein the polypeptide is characterized as:

    (a) promoting normal mitotic recombination, and

    (b) being essentially unable to repair a DNA double-strand break including those which occur at the cleavage site:

CAACAG
GTTGTC

12. The polypeptide of claim 11, wherein the break is induced by an endonuclease.

13. The polypeptide of claim 12, wherein the endonuclease is *HO*.

14. An antibody to the polypeptide of claim 11.

15. The antibody of claim 14, which is a monoclonal antibody.

16. An antibody to the polypeptide of claim 10.

17. The antibody of claim 16, which is a monoclonal antibody.

18. A method of identifying DNA encoding functional polypeptide with tyrosine kinase activity capable of restoring DNA double-strand break repair activity in the host of claim 6, which comprises:

(a) screening a library of DNA for sequences capable of producing the polypeptide; and

(b) identifying DNA encoding polypeptide capable of restoring double-strand break activity.

19. The method of claim 18, wherein the DNA is mammalian DNA.

20. The method of claim 19, wherein the mammalian DNA is human DNA.

21. The method of claim 18, wherein the screening detects structural similarities between members of the DNA library or expression products thereof and the screening means.

22. The method of claim 21, wherein the screening means are based on nucleic acid structure or antigenic structure.

23. The method of claim 18, wherein the screening detects functional similarities between the expression products of the DNA library and the tyrosine kinase activity of the host.

24. The method of claim 23, wherein the functional similarities are detected by complementation.

25. The method of claim 24, wherein the complementation measures restoration of resistance to a DNA double-strand break.

26. The method of claim 25, wherein the DNA double-strand break is induced by a radiomimetic alkylating agent.

27. The method of claim 26, wherein the radiomimetic alkylating agent has methylmethane sulfonate activity.

28. The method of claim 27, wherein the agent is methylmethane sulfonate.

29. The method of claim 25, wherein the DNA double-strand break is induced by an endonuclease.

30. The method of claim 29, wherein the endonuclease is *HO*.

31. The method of claim 25, wherein the DNA double-strand break is X-ray induced.

32. The method of claim 18, wherein the host is a yeast.

33. The method of claim 32, wherein the yeast is a member of the genus *Saccharomyces*.

34. The method of claim 33, wherein the yeast is *Saccharomyces cerevisiae*.

35. An isolated DNA sequence encoding a polypeptide with tyrosine kinase activity, wherein the polypeptide is capable of restoring DNA double-strand break repair activity in the host of claim 6.

36. The DNA sequence of claim 35, selected from the group consisting of:

(a) cDNA having a nucleotide sequence derived from the genomic coding region of the polypeptide;

(b) DNA sequences encoding an amino acid sequence having at least about 35% homology in the protein kinase domain with the amino acid sequence encoded by the cDNA of (a); and

(c) DNA sequences which are degenerate as a result of the genetic code with respect to the DNA sequences of (a) and (b).

37. The DNA sequence of claim 35, which is a mammalian DNA.

38. The mammalian DNA sequence of claim 37, which is a human DNA.

39. An isolated DNA sequence identified by the method of claim 18.

40. An isolated polypeptide capable of restoring DNA double-strand break repair activity in the host of claim 6 or functional fragments thereof, wherein the polypeptide is free from other polypeptides with which it is associated in nature.

41. An isolated polypeptide encoded by all or a functional portion of the DNA sequence of claim 35.

42. The polypeptide of claim 40, which is a mammalian polypeptide.

43. The mammalian polypeptide of claim 42, which is a human polypeptide.

44. An antibody to the polypeptide of claim 40.

45. The antibody of claim 44, which is a monoclonal antibody.

46. An antibody to the polypeptide of claim 41.

47. The antibody of claim 46, which is a monoclonal antibody.

48. A method for identifying a composition which affects the activity of a mammalian polypeptide having tyrosine kinase activity, wherein the polypeptide is capable of restoring DNA double-strand break repair activity in the host of claim 6, the method comprising:

(a) incubating components comprising the composition and the mammalian polypeptide in the presence of the host, wherein the incubating is carried out for a period of time and under conditions sufficient to allow the components to interact; and

(b) measuring the change in tyrosine kinase activity caused by the system.

49. The method of claim 48, wherein the change in step (b) correlates with decreased repair of DNA double-strand breaks.

50. The method of claim 49, wherein the DNA double-strand break is induced by a radiomimetic alkylating agent.

51. The method of claim 50, wherein the radiomimetic alkylating agent has methylmethane sulfonate activity.

52. The method of claim 51, wherein the agent is methylmethane sulfonate.

53. The method of claim 49, wherein the DNA double-strand break is induced by an endonuclease.

54. The method of claim 53, wherein the endonuclease is *HO*.

55. The method of claim 49, wherein the DNA double-strand break is X-ray induced.

56. The method of claim 48, wherein the affect of the molecule is to inhibit the polypeptide.

57. The method of claim 48, wherein the mammalian polypeptide is a human polypeptide.

```
HRR25     1/      MDLRVGRKFRIGRKIGSGSFGDIYHGTNLI---SGEEVAIKLESIRS----RHPQLDYESRVYRYLSG
CDC28     1/       MSGELANYKRLEKVGEGTYGVVYKALDLRPGQGQRVVALKKIRLESEDEGVPSTAIREISLLKELK
K991      1/  MARTITFDIPSQYKLVDLIGEGAYGTVCSAIHKP---SGIKVAIKKIQPFSKKL-FVIRTIREIKLIRYFHE
RAF1    346/            SEVMLSTRIGEGSFGTVYKGKWHG------DVAVKILKVVDPTPEQFQAFRNEVAVIRKT-R

HRR25    62/  GVGIPFIRWFGREG-----EYNAMVIDLLGPSLEDLFNYCHRR------FSFKTVIMLALQMFCRIQYIHGR
CDC28    66/  DDNIVRLYDIVHSDA----HKLYLVFEFLDL---DLKRYMEGIPKDQP-LGADIVKKFMMQLCKGIAYCHSH
K991     68/  HENIISILDKVRPVSIDKLNAVYLVEELMET---DLQKVINNQNSGFSTLSDDHVQYFTYQILRALKSIHSA
RAF1    401/  HVNILLFMGYMTK------DNLAIVTQWCEGS--SLYKHLHVQETK---FQMFQLIDIARQTAQGMDYLHAK

HRR25   123/  SFIHRDIKPDNFLMGVGRRGSTVHVIDFGLSKKYRDFNTHRHIP-YRENKSLTGTARYASVNTHL--GIEQ-
CDC28   116/  RILHRDLKPQNLLINKDG---NLKLGDFGLARAFGVPLRAY--------THEIVTLWYRAPELLL--GGKQY
K991    122/  QVIHRDIKPSNLLLNSNC---DLKVCDFGLARCLASSSDSRETLVGFMETEYVATRWYRAPEIML--TFQEY
RAF1    461/  NIIHRDMKSNNIFLHEGL---TVKIGDFGLATVKSRWSGSQQV------EQPTGSVLWMAPEVIRMQDNNPF

HRR25   190/  SRRDDLESLGYVLIYFCKGSLPWQGLKATTKKQKYDRIMEKKLNV---SVETLCSG----------------
CDC28   190/  STGVDTWSIGCIFAEMCNRKPIFSGDSEI---DQIFKIFRVLGTP--NEAIWPDIVYLPDFKPSFPQWRRKD
K991    203/  TTAMDIWSCGCILAEMVSGKPLFPGRDYH---HQLVLILEVLGTPSFEDFNQIKSKRAKEYIANLPMRPPLP
RAF1    524/  SFQSDVYSYGIVLYELMTGELPYSHI------NNRDQIIFMVGRG--YASPDLSKLYKN------------
```

FIG.1A

```
HRR25   243/  ---------LPLEFQEYMAYCKNLKFDEKPDYLFLARLFKDLSIKLEYHNDHLFDWTMLRYTKAMVEKQRDL
CDC28   257/  LSQVVPS--LDPRGIDLLDKLLAYDPINRISARRAAI--HPYFQES
K991    276/  WETVWSKTDLNPDMIDLLDKMLQFNPDKRISAAEA
RAF1    574/  ---------CPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSL

HRR25   288/  LIEKGDLNANSNAASASNSTDNKSETFNKIKLLAMKKFPTHFHYYKNEDKHNPSPEEIKQQTILNNNAASSL
HRR25   361/  PEELLNALDKGMENLRQQQPQQQVQSSQPQPQPQQLQQQPNGQRPNYYPEPLLQQQQRDSQEQQQQVPMATT
HRR25   451   RATQYPPQINSNNFNTNQASVPPQMRSNPQQPPQDKPAGQSIWL
```

FIG.1A(CONT.)



FIG.1B

INTERNATIONAL SEARCH REPORT

Int...national application No.
PCT/US92/05565

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :Please See Extra Sheet.
US CL :435/6, 15, 194, 240.1, 252.3, 320.1; 530/387.1, 388.26; 536/27
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.4, 15, 194, 240.1, 252.3, 320.1; 530/300, 350, 387.1, 388.26; 536/27

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	Journal of Cellular Biochemistry, Supplement 15A, issued 1991, M.F. Hoekstra et al, "A gene product from yeast associated with the repair of damaged DNA encodes a protein kinase", page 156, entire document .	1-13,35-41 14-34, 42-57
Y	S.L. Berger et al.,"Methods in Enzymology", Volume 152, published 1987 by Academic Press (N.Y.), pages vi-x, entire document.	18-34, 42-43
Y	"Methods in Enzymology", Volume 70, published 1980 by Academic Press (N.Y.), pages 49-70, entire document.	14-17, 44-47
Y	Biochemical and Biophysical Research Communications, Voulume 170, No. 1, issued 16 July 1990, D.C. Gaudette et al, "Effect of genistein, a tyrosine kinase inhibitor, on U46619-induced phosphoinositide phosphorylation in human platelets", pages 238-242, especially pages 239-240.	48-57

[X] Further [redacted] listed in the continuation of Box C. [ ] See patent family annex.

*	[redacted]	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 31 July 1992	Date of mailing of the international search report 10 AUG 1992
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer GABRIELE E. BUGAISKY Telephone No. (703) 308-4201

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/05565

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Science, Volume 241, issued 01 July 1988, S.K. Hanks et al, :The protein kinase family: Conserved features and deduced Phylogeny of the catalytic domains", pages 42-52, entire document.	1-57

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/05565

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (5):

C07H 21/04; C07K 15/00, 15/28; C12N 1/00, 5/10, 9/12, 15/00; C12Q 1/48, 1/68

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

Sequence Databases: Geneseq, Genbank/EMBL, PIR, SwissProt; APS; Dialog: Medline, Biosis, Embase, Biotech. Abs.

search terms: tyrosine kinase, ligase, ligation, recombination, repair, HO, endonuclease, nuclease, AU=Hoesktra, complement?, screen?, library, complementation, HHR, yeast, saccharomyces, enzyme, antibod?, monoclonal, DT=review, agonist, antagonist, inhibit?, activity